From Barchart: 2025-05-14 16:05:00

Biodesix, Inc. (NASDAQ:BDSX) received a “Buy” rating from Canaccord Genuity despite financial challenges. The company reported a quarterly loss of $0.08 per share, an improvement from last year. Q1 2025 revenue was $17.96 million, up 21% from the previous year, driven by lung diagnostic services. CEO Scott Hutton highlighted progress towards 2025 goals. The stock price is currently $0.22, down significantly from previous highs.



Read more at Barchart:: Biodesix, Inc. (NASDAQ:BDSX) Maintains “Buy” Rating Amid Financial Challenges